Press release
Dystrophic Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Dystrophic Epidermolysis Bullosa Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Dystrophic Epidermolysis Bullosa Pipeline Outlook Report [https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report
* In August 2025, Krystal Biotech Inc . announced a Phase 3 study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
* In August 2025, Castle Creek Biosciences LLC conducted a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
* DelveInsight's Dystrophic Epidermolysis Bullosa pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Dystrophic Epidermolysis Bullosa treatment.
* The leading Dystrophic Epidermolysis Bullosa Companies such as Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
* Promising Dystrophic Epidermolysis Bullosa Pipeline Therapies such as KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.
Discover how the Dystrophic Epidermolysis Bullosa treatment paradigm is evolving. Access DelveInsight's in-depth pipeline analysis for a closer look at promising breakthroughs @ Dystrophic Epidermolysis Bullosa Clinical Trials and Studies [https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dystrophic Epidermolysis Bullosa Emerging Drugs Profile
* PTR-01: Phoenix Tissue Repair
Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.
* FCX-007: Castle Creek Biosciences
D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.
The Dystrophic Epidermolysis Bullosa Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Dystrophic Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
* Dystrophic Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.
Get a detailed analysis of the latest innovations in the Dystrophic Epidermolysis Bullosa pipeline. Explore DelveInsight's expert-driven report today! @ Dystrophic Epidermolysis Bullosa Unmet Needs [https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dystrophic Epidermolysis Bullosa Companies
Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
Dystrophic Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Dystrophic Epidermolysis Bullosa Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Dystrophic Epidermolysis Bullosa Therapies and key Developments @ Dystrophic Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report
* Coverage- Global
* Dystrophic Epidermolysis Bullosa Companies- Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
* Dystrophic Epidermolysis Bullosa Pipeline Therapies- KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.
* Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Dystrophic Epidermolysis Bullosa drug development? Find out in DelveInsight's exclusive pipeline report-access it now! @ Dystrophic Epidermolysis Bullosa Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Dystrophic Epidermolysis Bullosa: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dystrophic Epidermolysis Bullosa - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* FCX-007: Castle Creek Biosciences
* Mid Stage Products (Phase II)
* PTR-01: Phoenix Tissue Repair
* Early Stage Products (Phase I/II)
* PTW-002: Phoenicis Therapeutics
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Dystrophic Epidermolysis Bullosa Key Companies
* Dystrophic Epidermolysis Bullosa Key Products
* Dystrophic Epidermolysis Bullosa- Unmet Needs
* Dystrophic Epidermolysis Bullosa- Market Drivers and Barriers
* Dystrophic Epidermolysis Bullosa- Future Perspectives and Conclusion
* Dystrophic Epidermolysis Bullosa Analyst Views
* Dystrophic Epidermolysis Bullosa Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dystrophic-epidermolysis-bullosa-pipeline-outlook-report-2025-key-15-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dystrophic Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4137650 • Views: …
More Releases from ABNewswire
Andrew Leigh Honors Women Who Changed the Course Of History In Conversations Wit …
Andrew Leigh, co-founder of Maynard Leigh Associates, a leading UK training provider and much-published business author, has made a striking literary debut with his first non-fiction and non-business book, Conversations with Remarkable Women .
The book comprises imaginary conversations with twenty distinguished and high-achieving women from history. Leigh offers readers a fresh perspective on the lives and legacies of figures such as Catherine the Great, Mary Wollstonecraft, Harriet Tubman, Coco Chanel,…
McKay Law Continues Legacy of Excellence in East Texas Truck Accident Representa …
Record-Breaking Results Speak powerfully for clients
EAST TEXAS - October 27, 2025 - McKay Law, one of East Texas's most respected personal injury law firms, today reaffirmed its position as the region's premier choice for truck accident victims seeking maximum compensation and dedicated legal representation. With a proven track record of multi-million dollar verdicts, rapid-response investigation protocols, and an unwavering commitment to client success, McKay Law continues to set the standard…
Zero-Friction Automation: Anno Robot Offers 'Lifetime System Maintenance' and 90 …
The global retail sector is undergoing its most profound transformation in decades, driven by a confluence of rising labor costs, persistent staffing shortages, and a consumer demand for instant, 24/7 service. In this rapidly evolving landscape, the future of commerce is increasingly defined by automation. At the forefront of this shift is Anno Robot, a Shenzhen-based National High-Tech Enterprise that is not just selling robotic equipment but engineering a 'zero-friction'…
Client from Burkina Faso visited the company for an inspection, jointly embarkin …
During the inspection, accompanied by the heads of the company's foreign trade department and technology department, the client successively visited our company's production factory, product exhibition center and R&D laboratory. In the production workshop, the customer closely observed the automated production process of WPC wall panels [https://www.haofabm.com/wpc-interior-wall-panels-are-waterproof-scratch-resistant-environmentally-friendly-formaldehyde-free-and-feature-multi-color-textures-product/] and PU insulation wall panels [https://www.haofabm.com/pu-insulation-wall-panels-one-board-solves-insulation-and-weather-resistance-reducing-building-energy-consumption-by-30-directly-product/], and inquired in detail about the raw material selection standards, production process control points and quality inspection…
More Releases for Dystrophic
Recessive Dystrophic Epidermolysis Bullosa (RDEB) market is expected to reach US …
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare, inherited connective tissue disorder caused by mutations in the COL7A1 gene, which impairs the production of type VII collagen. This results in fragile skin prone to blistering and chronic wounds even from minor friction or trauma. RDEB is one of the most severe forms of epidermolysis bullosa (EB), often leading to severe pain, recurrent infections, scarring, and increased risk of squamous cell…
Dystrophic Epidermolysis Bullosa (DEB) Market Emerging Trends and Growth Prospec …
Introduction
Dystrophic epidermolysis bullosa (DEB) is a rare and debilitating genetic skin disorder characterized by extreme fragility of the skin and mucous membranes, leading to chronic blistering, painful wounds, and scarring. Classified as a rare or "orphan" disease, DEB severely impacts quality of life, often resulting in severe complications including infections, malnutrition, and increased risk of squamous cell carcinoma.
Over the past decade, advances in genetic research, regenerative medicine, and biologic therapies…
Dystrophic Epidermolysis Bullosa Market Size Expected to Reach US$ 1,786.1 Milli …
Market Overview:
The dystrophic epidermolysis bullosa market reached a value of US$ 466.1 Million in 2022 and expects to reach US$ 1,786.1 Million by 2033, exhibiting a growth rate (CAGR) of 12.8% during 2023-2033.
The dystrophic epidermolysis bullosa market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available…
Dystrophic Epidermolysis Bullosa Treatment Market: Opportunity Analysis & Indust …
The global Retinal Disorders Treatment market is estimated to attain a valuation of US$ 19 Bn by the end of 2030, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 7% during the forecast period, 2020-2030.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders…
Dystrophic Epidermolysis Bullosa Management Market Competitive Intelligence b …
According to our (Global Info Research) latest study, the global Dystrophic Epidermolysis Bullosa Management market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Dystrophic Epidermolysis Bullosa Management…
Dystrophic Epidermolysis Bullosa Treatment Market to Develop Rapidly by 2030, TM …
The Global Dystrophic Epidermolysis Bullosa Treatment Market is estimated to attain a valuation of ~US$ 710 Mn by the end of 2030, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of ~5% during the forecast period, 2020 to 2030.
The key objective of the TMR report is to offer a complete assessment of the global market including…
